WALTHAM, Mass.--(BUSINESS WIRE)--Echosens North America, a high-technology company offering the FibroScan ® portfolio of solutions, recognizes the importance of American Diabetes Month this November ...
WALTHAM, Mass. & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Echosens North America, a high-technology company offering the FibroScan ® portfolio of solutions, and ChronWell, a digital health and ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Higher sex hormone-binding globulin levels may predict liver fibrosis for men with nonalcoholic ...
In this column, an endocrinologist discusses the growing problem of liver disease and new options at their disposal, including vibration-controlled transient elastography. A growing number of ...
Digital therapeutics (DTx), which provide evidence-based interventions through software programs, could benefit patients with nonalcoholic fatty liver disease (NAFLD), according to a new review. Few ...
Please provide your email address to receive an email when new articles are posted on . A high maternal pre-pregnancy BMI increases the risk of offspring developing non-alcoholic fatty liver disease, ...
LONDON — Resmetirom (Madrigal Pharmaceuticals) is a safe option for patients with nonalcoholic steatohepatitis (NASH), according to a pair of studies sharing results from the phase 3 MAESTRO NAFLD-1 ...
It’s often, “silent” – meaning it rarely presents with symptoms. Until it is severe. It is projected to be the number one cause of liver transplantation in the United States by the year 2030. And it’s ...
CONSHOHOCKEN, Pa., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides an update on MAESTRO-NAFLD-1, its 52-week Phase 3 multi-center, double-blind, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback